Is Wegovy going to get cheaper in the UK?

Why Wegovy prices have risen, not fallen, in recent years

NICE recommended semaglutide (Wegovy) for weight management in March 2023 under NICE Technology Appraisal TA875, which created a surge in demand that supply struggled to match. That supply pressure, combined with Eli Lilly's decision to raise Mounjaro's UK list price from around £122 to around £330 per four-week pen from 1 September 2025 (as widely reported in August 2025), set the broader private market tone. Novo Nordisk's pricing for Wegovy has followed a similar upward trajectory. Private providers currently price Wegovy treatment at roughly £149–£375 a month depending on dose and service, though these figures are subject to change and should be verified directly with any provider you are considering.

Demand remains high. The NHS rollout of tirzepatide under NICE TA1026 (described on the NHS England weight-management injections page) is phased and tied to strict clinical criteria, which means many people continue to seek private routes. When demand consistently exceeds supply at a manufacturer level, list prices tend not to fall. There is no publicly available evidence that Novo Nordisk has announced a UK price reduction for Wegovy.

That said, pricing in private markets can shift. Competition between providers, the arrival of the higher-dose 7.2mg pen approved by the MHRA in April 2026, and the MHRA's June 2026 approval of the oral Wegovy tablet all change the landscape. None of those approvals have translated into lower prices so far, but if you are wondering whether the Wegovy price is likely to come down, that page examines the factors at play in detail. If you want a regularly updated view of what Wegovy costs in the UK right now, that page is kept current.

What headline prices often leave out

When comparing prices across providers, it is worth reading the small print carefully. A headline monthly figure sometimes excludes the initial consultation fee, the prescription charge, delivery, and any clinical support between doses. A provider charging £149 for the pen but £50 for the consultation and £10 for delivery is not cheaper than one charging £200 all-in, it is just harder to compare at first glance.

Some services also operate on a subscription model that auto-renews without a fresh clinical review. For a prescription medicine whose dose is titrated over time, that matters: a repeat supply issued without reassessment is not just a commercial inconvenience, it is a clinical concern. The guide to getting Wegovy at a lower overall cost sets out what to look for when weighing up providers honestly.

At nume, the price shown on our treatment page is the full price. One amount covers the consultation, prescription, medicine and free next-working-day DPD delivery, your pen arrives in plain, unbranded packaging with a tracking link sent to your phone. Nothing is added at checkout. We review every repeat order clinically before dispatching anything.

Why nume being the cheapest option is not something we aim for

We are deliberately not the cheapest provider. That is a considered position, not an oversight. A real prescriber (not software) reads every consultation the same day it arrives. We run photo-ID and live weight verification. We notify your GP in line with GPhC guidance. We check Summary Care Records where appropriate. Those steps cost more to run than a fully automated process, and they matter for your safety.

For a prescription medicine, price is simply the wrong starting question. The right question is whether the supply chain is genuine, the clinical review is real, and the aftercare is accessible. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, some have contained insulin rather than semaglutide, and several hospitalisations have been linked to fake products. Any seller offering these medicines without a prescription, or at prices that seem implausibly low, should be treated as a serious red flag. You can verify any online pharmacy on the GPhC register; our registration number is 9012878.

If you would like to understand more about how the Wegovy price has moved or what factors might push it down, those pages go into more detail. The honest conclusion for now: meaningful price reductions are not guaranteed or imminent, and in the meantime the quality of the clinical service around the medicine matters as much as the figure on the invoice.

What to do if cost is genuinely a barrier

If private pricing feels out of reach, it is worth checking NHS eligibility. Under NICE TA875, semaglutide is available via specialist weight management services for patients meeting specific BMI and comorbidity criteria, though waiting lists are typically long, and the criteria are strict. From June 2026, Cohort 2 of the NHS tirzepatide rollout opened to people with a BMI of 35–39.9 plus four or more qualifying conditions, which may be relevant if you are considering weight-loss treatment options more broadly.

For people who do not meet NHS thresholds or prefer not to wait, our prescribers can assess whether Wegovy is clinically suitable through a free consultation. There is no charge to find out. If you are actively looking for ways to access Wegovy at a lower cost, that page brings together the most practical options currently available. If future UK pricing shifts make private treatment more accessible, we will reflect that, but we will not change the clinical rigour of the process to get there. Speak to our prescribers and see what your options look like today.